| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 7, 2022 |
| Accession Number: | 0001457612-22-000077 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
SC 13D/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SVB Leerink reiterated coverage of Genocea Biosciences with a rating of Outperform and set a new price target of $6.00 from $5.00 previously
Needham reiterated coverage of Genocea Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 1066689. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the third quarter ended September 30, 2021. "We continue to make significant progress. Most notably, we are very excited about our TiTAN™ clinical trial for GEN-011, our neoantigen-targeted peripheral T cell therapy (NPT) candidate, from which we expect to have initial data from a small subset of patient
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October 28th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 8729366. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will be available on the Genocea we
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company's ongoing operations and terminate the Company's remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the Nasdaq Capital Market in connection with the wind down of its operations. The Company plans to file a Form 25 with the Securities and Exchange Commission on or about June 2
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company, merger or reverse merger. As we pursue strategic alternatives, the Company has put into place a restructuring plan which includes an approximate 65% reduction in workforce in the second q
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial translational data corroborate clinical findings PLANETTM manufacturing process is highly reliable and continues to improve; patients next to be dosed to receive GEN-011 with substantially boosted yields, neoantigen specificity and potency Investor webcast at 4:30 pm ET today to further discuss data CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation n
15-12B - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. Genocea Biosciences, Inc. (NASDAQ:GNCA), which announced on May 24 plans to wind down of operations, continued to see weakness, ending the week down over 66%. The company is awaiting delisting of its stock from Nasdaq. Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE) shares also came under intense selling pressure after it announced the Food and Drug Administration's decision to issue a refusal-to-file letter for its Arginase 1 deficiency treatment candidate. The week witnessed some activity on the M&A front. GlaxoSmithKline plc (NYSE:GSK) confirmed the
Gainers NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) shares gained 47.5% to settle at $0.8436 on Thursday. Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) recently determined that the evaluation of NRx Pharmaceuticals’ Zyesami (aviptadil) should cease due to futility. Repare Therapeutics Inc. (NASDAQ:RPTX) surged 44.8% to close at $12.67 on Thursday after the company announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib. Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential milestones. Talk
On Tuesday, 36 companies achieved new lows for the year. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was Clearwater Analytics Hldg (NYSE:CWAN). The smallest company in terms of market cap to set a new 52-week low was Genocea Biosciences (NASDAQ:GNCA). Outlook Therapeutics (NASDAQ:OTLK)'s stock fell the most, as it traded down 37.33% to reach a new 52-week low. Burning Rock Biotech (NASDAQ:BNR)'s stock showed potential to rebound, rebounding up 0.69% after reaching a new 52-week low. On Tuesday, the following stocks set new 52-week lows: Clearwater Analytics Hldg (NYSE:CWAN) stock broke to a new 52-week low